Ranzoni, AM; Corcelli, M; Hau, K-L; Kerns, JG; Vanleene, M; Shefelbine, S; Jones, GN; ... Guillot, PV; + view all Ranzoni, AM; Corcelli, M; Hau, K-L; Kerns, JG; Vanleene, M; Shefelbine, S; Jones, GN; Moschidou, D; Dala-Ali, B; Goodship, AE; De Coppi, P; Arnett, TR; Guillot, PV; - view fewer (2016) Counteracting bone fragility with human amniotic mesenchymal stem cells. Scientific Reports , 6 , Article 39656. 10.1038/srep39656.

Text Arnett_published paper.pdf Download (1MB)

Abstract

The impaired maturation of bone-forming osteoblasts results in reduced bone formation and subsequent bone weakening, which leads to a number of conditions such as osteogenesis imperfecta (OI). Transplantation of human fetal mesenchymal stem cells has been proposed as skeletal anabolic therapy to enhance bone formation, but the mechanisms underlying the contribution of the donor cells to bone health are poorly understood and require further elucidation. Here, we show that intraperitoneal injection of human amniotic mesenchymal stem cells (AFSCs) into a mouse model of OI (oim mice) reduced fracture susceptibility, increased bone strength, improved bone quality and micro-architecture, normalised bone remodelling and reduced TNFα and TGFβ sigalling. Donor cells engrafted into bones and differentiated into osteoblasts but importantly, also promoted endogenous osteogenesis and the maturation of resident osteoblasts. Together, these findings identify AFSC transplantation as a countermeasure to bone fragility. These data have wider implications for bone health and fracture reduction.

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as CSVXMLJSON

Archive Staff Only

View Item